Risk Factors for gyrA and parC Mutations in Pseudomonas aeruginosa

Infection Control and Hospital Epidemiology

Volumn 36, Issue 4, 2015, Pages 387-393

  Cluzet, Valerie C ^a   Lautenbach, Ebbing ^a,b   Nachamkin, Irving ^b   Cary, Mark S ^b   Fishman, Neil O ^a   Shih, Natalie N C ^b   Morales, Knashawn H ^b   Linkin, Darren R ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MONOBACTAM DERIVATIVE; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; SULFONAMIDE; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV;

ADULT; ARTICLE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MUTATION; PSEUDOMONAS AERUGINOSA; RISK FACTOR; ANTIBIOTIC RESISTANCE; CROSS INFECTION; GENETICS; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CROSS INFECTION; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; VANCOMYCIN;

EID: 84955147819     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2014.87     Document Type: Article

References (28)

1. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005;41:848-854.
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-640.
3. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43-48.
4. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004;57:112-118.
5. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-1132.
6. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
7. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microbial Drug Resist 1998;4:257-261.
8. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agent 2005;25:290-295.
9. Qiang YZ, Qin T, Fu W, Cheng WP, Li YS, Yi G. Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother 2002;49:549-552.
10. Bagel S, Hullen V, Wiedemann B, Heisig P. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 1999;43:868-875.
11. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006; 119(526):e519-e525.
12. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005;55:535-541.
13. Baddour LM, Hicks DV, Tayidi MM, et al. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microbial Drug Resist 1995;1:219-222.
14. Paladino JA, Sunderlin JL, Forrest A, Schentag JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003;52:457-463.
15. Khayr W, Rheault W, Waiters L, Walters A. Epidemiology of ciprofloxacin-resistant Pseudomonas aeruginosa in a veterans affairs hospital. Am J Therapeut 2000;7:309-312.
16. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346-351.
17. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900.
18. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36: 8-27.
19. Baram D, Daroowalla F, Garcia R, et al. Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Resp Pulm 2008;2:19-25.
20. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306-1311.
21. Averill RF,Goldfield N, Steinbeck B, Grant T,Muldoon J, Brough J, Gay J. Development of the all patient refined DRGs (APR-DRGs). 3M HIS Research Report, 1997.
22. Institute of Clinical and Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. CLSI. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
23. Gorgani N, Ahlbrand S, Patterson A, Pourmand N. Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34:414-418.
24. Sanger Sequencing on ABI 3730. Perelman School of Medicine Department of Genetics DNA Sequencing Facility website. Available from: http://www.med.upenn.edu/genetics/dnaseq/sanger.shtml. Accessed July 22, 2014.
25. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907-916.
26. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-137.
27. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002;46:854-858.
28. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340-345.